(Finance) – BIOSANA SVASoperator of the health sector, active in the production and distribution of medical devices intended for public and private health facilities, listed on Euronext Growth Milan, has made it known that the Board of Directors examined the revenues consolidated to 31 December 2024, not subjected to legal review, which are equal to 120.2 million eurosgrowing 1.7% compared to the same period as the previous year (118.2 million).
“We are satisfied with the performance recorded by our foreign business units, Mark Medical and Bormia who have achieved a double -digit growth, respectively of 11.5% and 12.5%, developing in a complex and competitive market context thus confirming the validity of our expansion strategy in Eastern Europe markets – he commented Umberto PerillCEO of Svas Biosana -. Geographical and product diversification has allowed an overall increase in turnover of 1.7%, we have so consolidated the growth recorded in the last two years and obtained the best turnover of always 120.2 million euros. We look at 2025 with optimism and trust, strong of an efficient operating structure and a clear growth strategy, continuing to invest in product innovation and international expansion “.